MAOB and Parkinson disease: Problems in PD therapies include the short half-life and fluctuant plasma levels of levodopa, the precursor of dopamine [51]; variable effects of MAO-B [50]; and the short duration of entacapone and opicapone [52], as well as other troubles that necessitated the search for a viable different option.